Evidence map›Paper›PMID 27631533›Full record

ArticleMolecular diversity2016

Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files.

Andrew S Bell, Joseph Bradley, Jeremy R Everett, Jens Loesel, David McLoughlin, James Mills, Marie-Claire Peakman, Robert E Sharp, Christine Williams, Hongyao Zhu

Open access · hybridAbstract read
In one paragraph

Article in Molecular diversity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Novel Thienopyrimidine Inhibitors ofJournal of medicinal chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Andrew S BellPfizer Worldwide Research & Development, Sandwich, Kent, UK.
Joseph BradleyPfizer Worldwide Research & Development, Sandwich, Kent, UK.
Jeremy R EverettPfizer Worldwide Research & Development, Sandwich, Kent, UK. j.r.everett@greenwich.ac.uk.ORCID http://orcid.org/0000-0003-1550-4482
Jens LoeselPfizer Worldwide Research & Development, Sandwich, Kent, UK.
David McLoughlinPfizer Worldwide Research & Development, Sandwich, Kent, UK.
James MillsPfizer Worldwide Research & Development, Sandwich, Kent, UK.
Marie-Claire PeakmanPfizer Worldwide Research and Development, Groton, CT, USA.
Robert E SharpPfizer Worldwide Research and Development, Groton, CT, USA.
Christine WilliamsPfizer Worldwide Research & Development, Sandwich, Kent, UK.
Hongyao ZhuPfizer Worldwide Research and Development, Groton, CT, USA.
Pfizer (United Kingdom) · GBPfizer (United States) · USEli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput screening (HTS) is an effective method for lead and probe discovery that is widely used in industry and academia to identify novel chemical matter and to initiate the drug discovery process. However, HTS can be time consuming and costly and the use of subsets as an efficient alternative to screening entire compound collections has been investigated. Subsets may be selected on the basis of chemical diversity, molecular properties, biological activity diversity or biological target focus. Previously, we described a novel form of subset screening: plate-based diversity subset (PBDS) screening, in which the screening subset is constructed by plate selection (rather than individual compound cherry-picking), using algorithms that select for compound quality and chemical diversity on a plate basis. In this paper, we describe a second-generation approach to the construction of an updated subset: PBDS2, using both plate and individual compound selection, that has an improved coverage of the chemical space of the screening file, whilst only selecting the same number of plates for screening. We describe the validation of PBDS2 and its successful use in hit and lead discovery. PBDS2 screening became the default mode of singleton (one compound per well) HTS for lead discovery in Pfizer.

Indexed as

AlgorithmsComputer SimulationDrug DiscoveryDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysReproducibility of ResultsSmall Molecule LibrariesSmall Molecule Libraries2nd GenerationDiversityHigh-throughput screening (HTS)Lead discoveryPlate-basedRo40Rule of 40Screening fileSubset

Identifiers

PMID27631533
PMCPMC5055576
OpenAlexW2510729407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.